Lifeline Biotechnologies Inc
Lifeline Biotechnologies, Inc. operates as a medical technology company in the United States. Its technologies focus on prevention, early diagnosis, and quick recovery of various diseases. The company offers First Warning System, a non-invasive, non-compressive, and non-radiogenic device used in assisting the early discovery of breast tissue abnormalities in women. It also provides Mastascope, a … Read more
Lifeline Biotechnologies Inc (LLBO) - Total Liabilities
Latest total liabilities as of December 2009: $616.69K USD
Based on the latest financial reports, Lifeline Biotechnologies Inc (LLBO) has total liabilities worth $616.69K USD as of December 2009.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Lifeline Biotechnologies Inc - Total Liabilities Trend (2003–2018)
This chart illustrates how Lifeline Biotechnologies Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Lifeline Biotechnologies Inc Competitors by Total Liabilities
The table below lists competitors of Lifeline Biotechnologies Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Liquid Holdings Group Inc
PINK:LIQDQ
|
USA | $3.84 Million |
|
Applied Visual Sciences Inc
PINK:APVS
|
USA | $14.48 Million |
|
Praetorian Property Inc
PINK:PRRE
|
USA | $17.88 Million |
|
Gncc Capital Inc.
PINK:GNCP
|
USA | $940.17K |
|
Azteca Gold Corp
PINK:AZGFF
|
USA | $5.40 Million |
|
BPI Energy Holdings Inc
PINK:BPIGF
|
USA | $13.19 Million |
|
Falken Industries
PINK:FLKI
|
USA | $3.69 Million |
Liability Composition Analysis (2003–2018)
This chart breaks down Lifeline Biotechnologies Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lifeline Biotechnologies Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lifeline Biotechnologies Inc (2003–2018)
The table below shows the annual total liabilities of Lifeline Biotechnologies Inc from 2003 to 2018.
| Year | Total Liabilities | Change |
|---|---|---|
| 2018-12-31 | $385.79K | -4.69% |
| 2017-12-31 | $404.78K | -11.50% |
| 2016-12-31 | $457.39K | +28.34% |
| 2015-12-31 | $356.38K | -42.21% |
| 2009-12-31 | $616.69K | -43.44% |
| 2004-12-31 | $1.09 Million | +189.17% |
| 2003-12-31 | $377.03K | -- |